Pilot study comparing the Childhood Arthritis &amp; Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans
Creators: name: Kimura, Yukiko
name: Grevich, Sriharsha
name: Beukelman, Timothy
name: Morgan, Esi
name: Nigrovic, Peter A.
name: Mieszkalski, Kelly
name: Graham, T. Brent
name: Ibarra, Maria
name: Ilowite, Norman
name: Klein-Gitelman, Marisa
name: Onel, Karen
name: Prahalad, Sampath
name: Punaro, Marilynn
name: Ringold, Sarah
name: Toib, Dana
name: Van Mater, Heather
name: Weiss, Jennifer E.
name: Weiss, Pamela F.
name: Schanberg, Laura E.
name: Abramson, L.
name: Anderson, E.
name: Andrew, M.
name: Battle, N.
name: Becker, M.
name: Benham, H.
name: Birmingham, J.
name: Blier, P.
name: Brown, A.
name: Brunner, H.
name: Cabrera, A.
name: Canter, D.
name: Carlton, D.
name: Caruso, B.
name: Ceracchio, L.
name: Chalom, E.
name: Chang, J.
name: Charpentier, P.
name: Clark, K.
name: Dean, J.
name: Dedeoglu, F.
name: Feldman, B.
name: Ferguson, P.
name: Fox, M.
name: Francis, K.
name: Gervasini, M.
name: Goldsmith, D.
name: Gorton, G.
name: Gottlieb, B.
name: Griffin, T.
name: Grosbein, H.
name: Guppy, S.
name: Haftel, H.
name: Helfrich, D.
name: Higgins, G.
name: Hillard, A.
name: Hollister, J. R.
name: Hsu, J.
name: Hudgins, A.
name: Hung, C.
name: Huttenlocher, A.
name: Imlay, A.
name: Imundo, L.
name: Inman, C. J.
name: Jaqith, J.
name: Jerath, R.
name: Jung, L.
name: Kahn, P.
name: Kapedani, A.
name: Kingsbury, D.
name: Klein, K.
name: Kunkel, A.
name: Lapidus, S.
name: Layburn, S.
name: Lehman, T.
name: Lindsley, C.
name: Macgregor-Hannah, M.
name: Malloy, M.
name: Mawhorter, C.
name: McCurdy, D.
name: Mims, K.
name: Moorthy, N.
name: Morus, D.
name: Muscal, E.
name: Natter, M.
name: Olson, J.
name: O'Neil, K.
name: Orlando, M.
name: Palmquist, J.
name: Phillips, M.
name: Ponder, L.
name: Puplava, D.
name: Quinn, Steve
name: Quintero, A.
name: Rabinovich, C.
name: Reed, A.
name: Reed, C.
name: Riordan, M.
name: Roberson, S.
name: Robinson, A.
name: Rossette, J.
name: Rothman, D.
name: Russo, D.
name: Ruth, N.
name: Schikler, K.
name: Sestak, A.
name: Shaham, B.
name: Sherman, Y.
name: Simmons, M.
name: Singer, N.
name: Spalding, S.
name: Stapp, H.
name: Syed, R.
name: Thomas, E.
name: Torok, K.
name: Trejo, D.
name: Tress, J.
name: Upton, W.
name: Vehe, R.
name: von Scheven, E.
name: Walters, L.
name: Welnick, N.
name: White, A.
name: Woo, J.
name: Wootton, J.
name: Yalcindag, A.
name: Zapp, C.
name: Zemel, L.
name: Zhu, A.
Publisher: name: Swinburne
Year: 2024

description: Objectives: To assess the feasibility of studying the comparative effectiveness of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) consensus treatment plans (CTPs) for systemic Juvenile Idiopathic Arthritis (JIA) using an observational registry. Methods: Untreated systemic JIA patients enrolled in the CARRA Registry were begun on one of 4 CTPs chosen by the treating physician and patient/family (glucocorticoid [GC] alone. methotrexate [MTX] ± GC; IL1 inhibitor [IL1i] ± GC; IL6 inhibitor [IL6i] ± GC). The primary outcome of clinical inactive disease (CID) without current GC use was assessed at 9 months. Trial registration: clinicaltrials.gov NCT01697254; first registered 9/28/12 (retrospectively enrolled). Results: Thirty patients were enrolled at 13 sites; eight patients were started on a non-biologic CTP (2 GC, 6 MTX) and 22 patients on a biologic CTP (12 IL1i, 10 IL6i) at disease onset. Demographic and disease features were similar between CTP groups. CTP choice appeared to segregate by site preference. CID off GC was achieved by 37% (11 of 30) including 11/22 (50%) starting a biologic CTP compared to 0/8 starting a non-biologic CTP (p = 0.014). There were four serious adverse events: two infections, one appendicitis and one macrophage activation syndrome. Conclusions: The CARRA systemic JIA CTP pilot study demonstrated successful implementation of CTPs using the CARRA registry infrastructure. Having demonstrated feasibility, a larger study using CTP response to better determine the relative effectiveness of treatments for new-onset systemic JIA is now underway.